Physician

Neil Belman, DO

Study Coordinator

Carolyn Seith
email: Carolyn.Seith@sluhn.org
phone: 484-658-1789

 

Close

This is an observational research, or registry study that is non-interventional. The purpose of the research is to understand treatment patterns and the effectiveness of drugs used in the treatment of Multiple Myeloma. This registry previously involved two groups (Cohort 1 and Cohort 2) with newly diagnosed Multiple Myeloma. Cohort 3 will enroll participants with relapsed/refractory Multiple Myeloma who have received prior therapy for Multiple Myeloma.

Close

• Patients must be at least 18 years of age at time of initial diagnosis of symptomatic Multiple Myeloma (MM)
• Patients must be able and willing to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel
• Patients must have received prior 1st line therapy for symptomatic active MM and subsequently have evidence of clinical disease progression that warrants 2nd line treatment
• Patients must have started 2nd line therapy after the first relapsed/refractory diagnosis date OR intend to start 2nd line therapy shortly after enrollment on this registry
• Patients must have started 2nd line therapy and be enrolled on study within 60 days of the first relapse/disease progression date
• Patients may not be receiving an investigational product as part of their therapy for MM

Close